Advertisement
Advertisement
U.S. Markets close in 5 hrs 31 mins
Advertisement
Advertisement
Advertisement
Advertisement

RenovoRx, Inc. (RNXT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0000+0.0200 (+1.01%)
As of 04:00PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9800
Open1.9400
Bid1.8000 x 1000
Ask2.0400 x 800
Day's Range1.9000 - 2.0500
52 Week Range1.5000 - 16.7400
Volume9,593
Avg. Volume27,796
Market Cap17.816M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • Business Wire

    RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022

    LOS ALTOS, Calif., June 09, 2022--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that they will host a webinar highlighting their RenovoTAMP™ therapy platform. The webinar, "Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform," will be held on Tuesday, June 21st at 8:00 am (ET). To register for this event, click here.

  • Business Wire

    RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022

    LOS ALTOS, Calif., June 02, 2022--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway to Translation Webinar Series hosted by the University of Cambridge’s Academy of Therapeutic Sciences (CATS) on Wednesday, June 8, 2022 at 1:00 PM ET. Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx, will present a seminar, "Localized Intra-arterial Drug Delivery for Treatment of Solid Tumo

  • Business Wire

    RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer

    LOS ALTOS, Calif., May 19, 2022--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the Global Embolization Oncology Symposium Technologies (GEST) 2022, today in New York City. The study demonstrates the potential utility of RenovoRx’s proprietary Trans-Ar

Advertisement
Advertisement